Combination therapy with Bcl6 inhibitor FX1 and anti-PDL1 repressed the tumor growth of murine HNSCC. (IMAGE)
Caption
(A) The sketch of the therapy: C3H mice implanted with SCC7 (1 × 106/mouse) on the left flanks were randomly divided into four groups on day 5. Mice in the FX1 group and the combination group were intraperitoneally injected with FX1 (70 mg/kg) daily from day 5 for consecutive 8 days. Mice in the anti-PDL1 group and the combination group were intraperitoneally injected with anti-PDL1 (150 μg) at days 6, 8, 10, and 12. (B) Tumor growth curves of treated mice. (C) Pictures of tumor samples harvested at day 14. (D) Statistical diagram of tumor weight. (E) The proportion of Treg cells and the ratio of Treg cells to CD44+ CD8+ T cells. (F) Expression level of Foxp3, CD25, GITR, and ICOS in Treg cells. Data were presented as mean ± standard error of the mean and were calculated by two-way ANOVA (tumor growth curve) or one-way ANOVA; n ≥ 8; data in each panel are representative of at least two independent experiments; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001.
Credit
Genes & Diseases
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND